Does bronchoalveolar lavage lymphocytosis predict prognosis in fibrotic hypersensitivity pneumonitis, and is this relationship influenced by low-dose immunomodulatory therapy at the time of BAL?

Information from the abstract

Background Bronchoalveolar lavage (BAL) lymphocytosis is associated with improved prognosis in fibrotic hypersensitivity pneumonitis (fHP), although its prognostic value is unclear in patients receiving immunomodulatory treatment. We investigated whether treatment tapered to the lowest tolerated level at the time of BAL modifies associations with disease severity, one-year lung function, and transplant-free survival. Methods We analysed 247 fHP patients undergoing BAL, including 162 untreated and 85 receiving immunomodulatory therapy at the time of BAL. Associations between BAL lymphocytosis and baseline composite physiologic index (CPI), one-year CPI change, and transplant-free survival were assessed using multivariable flexible parametric survival models incorporating treatment status and interaction terms, adjusted for covariates. Results Mean age was 63 years, 43% male, 37% ever-smokers. Treated patients at the time of BAL were younger, with more severe disease (higher CPI). Mean BAL lymphocyte percentages were similar between two groups and inversely associated with baseline CPI in both. Higher BAL lymphocyte% were associated with more favourable CPI change in both untreated (−1.7 points per 10% increase; 95%CI −2.5–−0.8, p < 0.0001) and treated patients at BAL (−2.0 points; 95% CI −3.1–−0.9, p < 0.0001), with no treatment-by-BAL lymphocyte interaction ( p = 0.64). Higher BAL lymphocyte% independently predicted lower mortality both in untreated (HR 0.87 per 10% increase, p = 0.036) and treated patients at the time of BAL (HR 0.78, p = 0.025), with no treatment-by-BAL lymphocyte interaction ( p = 0.39). Conclusion BAL lymphocytosis was associated with less severe disease, favourable one-year CPI change and better survival, irrespective of background immunomodulatory therapy.

Why this record is monitored

This record has an Impact Signal of 76/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.

Related topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Inflammatory Myopathies and Dermatomyositis · Cancer Immunotherapy and Biomarkers